Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) was $27.18 for the day, down -0.15% from the previous closing price of $27.22. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 0.89 million shares were traded. AGIO stock price reached its highest trading level at $27.24 during the session, while it also had its lowest trading level at $26.56.
Ratios:
Our analysis of AGIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.39 and its Current Ratio is at 13.82. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 20, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $34.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 19, 2025, while the target price for the stock was maintained at $28.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 30 ’25 when Burns James William sold 2,932 shares for $27.09 per share. The transaction valued at 79,428 led to the insider holds 31,718 shares of the business.
Goff Brian sold 18,703 shares of AGIO for $506,664 on Dec 30 ’25. The Chief Executive Officer now owns 136,583 shares after completing the transaction at $27.09 per share. On Dec 30 ’25, another insider, Gheuens Sarah, who serves as the Chief Medical Officer of the company, sold 2,932 shares for $27.09 each. As a result, the insider received 79,428 and left with 64,795 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1584969472 and an Enterprise Value of 676624384. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.39 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at 15.106 whereas that against EBITDA is -1.439.
Stock Price History:
The Beta on a monthly basis for AGIO is 0.89, which has changed by -0.18962431 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, AGIO has reached a high of $46.00, while it has fallen to a 52-week low of $22.24. The 50-Day Moving Average of the stock is -17.74%, while the 200-Day Moving Average is calculated to be -20.51%.
Shares Statistics:
AGIO traded an average of 1.47M shares per day over the past three months and 2020720 shares per day over the past ten days. A total of 58.28M shares are outstanding, with a floating share count of 54.95M. Insiders hold about 5.77% of the company’s shares, while institutions hold 101.97% stake in the company. Shares short for AGIO as of 1765756800 were 6126003 with a Short Ratio of 4.16, compared to 1763078400 on 4331538. Therefore, it implies a Short% of Shares Outstanding of 6126003 and a Short% of Float of 10.58.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$1.84, with high estimates of -$1.7 and low estimates of -$2.03.
Analysts are recommending an EPS of between -$5.58 and -$7.39 for the fiscal current year, implying an average EPS of -$7.01. EPS for the following year is -$6.48, with 10.0 analysts recommending between -$4.82 and -$7.57.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $13.4M to a low estimate of $9M. As of. The current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $10.73MFor the next quarter, 10 analysts are estimating revenue of $16.64M. There is a high estimate of $21.05M for the next quarter, whereas the lowest estimate is $14.37M.
A total of 10 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $47.5M, while the lowest revenue estimate was $43.34M, resulting in an average revenue estimate of $45.77M. In the same quarter a year ago, actual revenue was $36.5MBased on 10 analysts’ estimates, the company’s revenue will be $108.93M in the next fiscal year. The high estimate is $191.3M and the low estimate is $67.25M.
